The Recombinant Cynomolgus CLEC12A/MICL/CLL-1 Protein is a high-quality recombinant protein produced for advanced research applications in molecular biology and biotechnology. This protein serves as a critical reagent in various experimental contexts, including functional studies, binding assays, and therapeutic development programs, providing researchers with a standardized and reliable tool for investigating protein function and interactions.
This product (SKU: RPCB1741) is produced using HEK293 cells and features a N-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 24.6 kDa with an observed molecular weight of 38-50 kDa under denaturing conditions, achieving ≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC., ensuring exceptional quality and consistency for research applications.
High quality, high purity and low endotoxin recombinant Recombinant Cynomolgus CLEC12A/MICL/CLL-1 Protein (RPCB1741), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC.
Reconstitution:
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.
Recombinant Cynomolgus CLEC12A/MICL/CLL-1 Protein was determined by Tris-Bis PAGE under reducing conditions.
The purity of Cynomolgus CLEC12A is greater than 95% as determined by SEC-HPLC.
